Skip to main content

Table 1 Randomized studies evaluating the role of high-dose chemotherapy in high-risk breast cancer

From: Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial

Author

Patients

Selection

Conventional arm

High-dose arm

RFS analysis

Rodenhuis [1]

885

4+ nodes

5×FEC

4×FEC - CTC

HD better (P = 0.08)

Peters [2]

785

10+ nodes

4×CAF + ID-CPB

4×CAF + HD-CPB

No difference, HD fewer relapses

Tallman [3]

540

10+ nodes

6×CAF

6×CAF + CT

No difference, HD fewer relapses

Roché

314

8+ nodes

4×FEC

4×FEC + CMA

HD better (P = 0.002)

Tokuda

97

10+ nodes

6×CAF

6×CAF + CT

HD better (NS)

Rodenhuis

81

Infraclav biopsy

4×FEC

4×FEC + CTC

No difference, HD less relapses

  1. CAF, cyclophosphamide, doxorubicin, fluorouracil; CMA, cyclophosphamide, mitoxantrone and melphalan; CT, cyclophosphamide and thiotepa; CTC, cyclophosphamide, thiotepa and carboplatin; FEC, fluorouracil, epirubicin, cyclophosphamide; nodes, tumor-positive axillary lymph nodes; HD-CPB, high-dose cyclophosphamide, cisplatin and BCNU; ID-CPB, intermediate-dose cyclophosphamide, cisplatin and BCNU.